The Role of Autologous Stem Cell Transplantation in the Treatment of Diffuse Large B-cell Lymphoma in the Era of CAR-T Cell Therapy
Abstract. For many years now and based on the results of the PARMA trial, relapsed Diffuse Large B-cell Lymphoma (DLBCL) is treated with salvage combination cytotoxic chemotherapy (most often platinum-based) followed by high dose myeloablative chemotherapy and autologous stem cell transplantation (a...
Main Authors: | Lazaros J. Lekakis, Craig H. Moskowitz |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2019-12-01
|
Series: | HemaSphere |
Online Access: | http://journals.lww.com/10.1097/HS9.0000000000000295 |
Similar Items
-
OUTCOME OF PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA RELAPSING AFTER AUTOLOGOUS TRANSPLANT BEFORE AVAILABILITY OF CAR-T CELL TREATMENT
by: Ulrike Bacher, et al.
Published: (2023-04-01) -
Twenty Years of Autologous Stem Cell Transplantation in Diffuse Large B-Cell Lymphoma: A Single Portuguese Center Experience
by: Margarida Dantas Brito, et al.
Published: (2016-03-01) -
P1165: BETALUTIN® IN PATIENTS WITH RELAPSED/ REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) NOT ELIGIBLE FOR AUTOLOGOUS STEM CELL TRANSPLANT
by: T. Illidge, et al.
Published: (2022-06-01) -
The significance of upfront autologous stem cell transplantation for high‐intermediate/high‐risk stage IV diffuse large B‐cell lymphoma
by: Aleksei K. Koviazin, et al.
Published: (2023-04-01) -
Transplant in Diffuse Large B-Cell Lymphoma
by: Guilherme Duffles, et al.
Published: (2022-06-01)